Search

everythinglearnresearchcommunity

for

Search:↓

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Women have a higher risk of blood clots from hormonal factors and need careful treatment, especially during pregnancy.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.

Regulating certain sex hormones may help delay facial aging.

Testosterone therapy for postmenopausal women appears safe and may protect against heart disease, but requires constant monitoring and more research for long-term effects.

The levonorgestrel intrauterine device for heavy periods may cause acne, hair loss, and excess hair growth.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Adding anti-Müllerian hormone to PCOS criteria lowers the number of women diagnosed.

High doses of cyproterone acetate are linked to an increased risk of developing meningioma.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The contraceptive implant Implanon may be linked to hair loss, but the reported case of alopecia could be unrelated to the implant.

Using high doses and multiple drugs with steroids is risky and should be prevented.

Using anabolic-androgenic steroids can harm men's reproductive health and increase the risk of heart problems and death.

5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.

Finasteride can have lasting negative effects on brain function and behavior by disrupting neurosteroid production.

First-time mothers had higher stress hormone levels in late pregnancy than mothers who had given birth before.

Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.

Researchers developed a method to detect hormone-blocking drugs in wastewater and found them in Beijing's sewage, suggesting they can survive sewage treatment.

Hormone therapies like birth control pills and spironolactone are safe and effective for treating women's adult acne.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Hormonal treatment is effective for women with acne not helped by usual treatments, especially if they have hormonal imbalances.

Anabolic steroid users may face higher risk of severe COVID-19.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

Finasteride safely treats hair loss without harming hormones or reproduction, but may slightly reduce sexual function.

Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.

Women with PCOS have lower adiponectin hormone levels and are more likely to have insulin resistance.

Future hormone therapy trials should match the diverse needs and priorities of the gender-diverse community.